Lyrica potentiate opiates

Added: Kolby Falgout - Date: 23.02.2022 18:17 - Views: 40971 - Clicks: 8277

Study record managers: refer to the Data Element Definitions if submitting registration or information. Neuropathic pain is frequently diagnosed as a complication of cancer pain. While opioids are the mainstay of cancer pain management,their efficacy in neuropathic pain seems to be less then optimal,and adjuvant drugs, mainly anticonvulsants and antidepressants,are often combined with opioids in the analgesic regimen of patients with neuropathic cancer pain.

This approach is suggested by well-established guidelines, but the analgesic benefit and the safety of pregabalin and oxycodone in combination is not yet documented. The aim of this study is to assess the activity and tolerability of the addition of pregabalin to oxycodone in the treatment of patients with neuropathic pain due to neoplasm. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision.

Talk with your doctor and family members or friends about deciding to a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or information. Search for terms. Save this study. Warning You have reached the maximum of saved studies Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : February 2, Study Description. The aim of the study is to assess tolerability and activity of oxycodone and pregabalin in combination for the treatment of oncological neuropathic pain with two different strategies. Detailed Description:. FDA Resources. Arms and Interventions. For 15 days or until unacceptable toxicity develops. Outcome Measures. Eligibility Criteria. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. Publications: Merskey H, Bugduk N. Classification of chronic pain. Description of chronic pain. Description of chronic pain syndromes and definitions of chronic pain terms. Seattle: IASP, press Minerva Anestesiol. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients.

Support Care Cancer. Epub Jun Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. Management of chronic neuropathic pain with methadone: a review of 13 cases.

Clin J Pain. Gralow I. Cancer pain: an update of pharmacological approaches in pain therapy. Curr Opin Anaesthesiol. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology Williston Park. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Assessment of cancer pain: a prospective evaluation in cancer patients referred to a pain service.

The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain and loss of function in head and neck cancer survivors. J Pain Symptom Manage. Validation of World Health Organization Guidelines for cancer pain relief: a year prospective study. Caraceni A. Clinicopathologic correlates of common cancer pain syndromes. Hematol Oncol Clin North Am.

Elliott KJ. Taxonomy and mechanisms of neuropathic pain. Semin Neurol. Kalso E. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. Gabapentin in the treatment of neuropathic pain. Palliat Med. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.

J Palliat Med. Pregabalin: in the treatment of postherpetic neuralgia. Davis MP. What is new in neuropathic pain? Epub Nov Pregabalin for the treatment of painful neuropathy. Expert Rev Neurother. Epub Dec 6. Randomized phase II clinical trials. Cancer Treat Rep. J Palliat Care. Randomised phase II trial NCT evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.

PLoS One. Epub Apr 5. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Cancer Pain. Drug: oxycodone Drug: pregabalin. Phase 2. Study Type :. Interventional Clinical Trial. Estimated Enrollment :. Study Start Date :. Actual Primary Completion Date :. Actual Study Completion Date :. Gabriella Farina, Fatebenefratelli and Ophtalmic Hospital. March 18, Key Record Dates.

Lyrica potentiate opiates

email: [email protected] - phone:(760) 638-8402 x 3442

Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain